This is really interesting. We’re busy looking at ways of using the power of LLMs to improve the user experience on Trip. One recent set of experiments relates to automated evidence reviews. While the following was semi-automatic it it is entirely possible to fully automate this. The review was exploring Brexpiprazole in schizophrenia and the overall report was three pages long and this included asking the system to generate both a conclusion and a clinical bottom line:

 

Clinical bottom line: Brexpiprazole shows efficacy in treating schizophrenia with most randomized controlled trials reporting it as ‘effective’, especially at non-low doses. However, its effectiveness compared to certain other antipsychotics can vary, and further studies are needed to assess its cognitive benefits.

Conclusion: Brexpiprazole’s efficacy in treating schizophrenia has been studied in several contexts. A systematic review from 2022 has raised concerns about the efficacy of low-dose brexpiprazole as it was not found to be superior to placebo or standard-dose brexpiprazole. However, another systematic review from 2023 suggests that while brexpiprazole may be less effective than a specific dose of lurasidone (160 mg), it generally demonstrates comparable efficacy and safety to both lurasidone and cariprazine.

Guidelines have noted some promising indications of brexpiprazole’s efficacy on cognitive performance in the context of second-generation antipsychotic compounds. Still, they have highlighted the need for further studies to accurately evaluate the extent of such benefits.

Randomized controlled trials (RCTs) have provided mixed but mostly positive feedback. The majority of the RCTs mentioned rated the effectiveness of brexpiprazole as ‘effective’. Notably, these trials reported consistent improvements in PANSS scores, maintained improvements over time, and a favorable side-effect profile. Only one RCT gave a ‘neutral’ rating, mainly due to mixed findings and potential bias introduced by the known side effects of an active reference.

Taking into account the weight typically given to systematic reviews and guidelines, the evidence suggests that brexpiprazole has some efficacy in treating schizophrenia, especially when not considering the low-dose. However, its effectiveness compared to some other antipsychotic compounds may vary, and further studies are recommended to determine its full range of benefits, especially in cognitive performance.

This is amazing technology and we’ll continue to test the capabilities.